ALGS - Aligos Therapeutics, Inc.
Previous close
41.55
-0.170 -0.409%
Share volume: 2,934
Last Updated: Fri 27 Dec 2024 08:21:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$41.72
-0.17
-0.41%
Fundamental analysis
24%
Profitability
25%
Dept financing
10%
Liquidity
73%
Performance
15%
Performance
5 Days
11.63%
1 Month
88.65%
3 Months
439.43%
6 Months
11,313.16%
1 Year
5,773.51%
2 Year
4,417.71%
Key data
Stock price
$41.55
DAY RANGE
$39.98 - $43.82
52 WEEK RANGE
$0.38 - $43.94
52 WEEK CHANGE
$6,431.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Lawrence M. Blatt
Region: US
Website: www.aligos.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.aligos.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)
Recent news